1) This sub-classification has led to the development of b 1 -and b 2 -AR antagonists and/or agonists which have been useful for the treatment of cardiovascular diseases and asthma. In early 1980s, a third b-AR, initially referred to as "atypical"
Early b 3 -AR agonists (the "first generation" of potent and selective rat b 3 -AR agonists) such as BRL 37344 (BRL 35135), [22] [23] [24] CL 316243, [25] [26] [27] and SR 58611A, 28) having a 3-chlorophenyl moiety in the left-hand side (LHS) and a carboxylic acid or an ester functionality in the right-hand side (RHS) as shown in Chart 1, have been reported to be effective anti-obesity and anti-diabetic agents in rodents. 29) These compounds, through their potent agonistic activity for the b 3 -AR, stimulate lipolysis and energy expenditure and cause only a slight increase in heart rate (b 1 -AR activity) and weak muscle tremor (b 2 -AR activity). Unfortunately, some of these early b 3 -AR agonists developed for the treatment of metabolic disorders failed to produce similar effects in humans, due to a lack of selectivity and/or potency, or poor pharmacokinetics. 30) Because of structural differences between human and rat b 3 -ARs with regard to the amino acid sequences of each receptor, activity at the rat b 3 -AR could not effectively predict that at the human b 3 -AR. 31) Thus, a new generation of human b 3 -AR agonists with minimal side effects associated with activation of human b 1 -and b 2 -ARs has long been needed.
A new generation of b 3 -AR agonists currently under preclinical development is represented by the tetrahydroisoquinoline 1, [32] [33] [34] SB 226552, 35, 36) L 755507, 37) L 770644, 38, 39) and LY-377604 40) (Chart 1). These compounds having both potent and full agonistic activity, and high selectivity at the human b 3 -AR were, in primary screening assays, evaluated in Chinese hamster ovary (CHO) cells expressing the cloned human b 3 -AR. This method of evaluation was believed to be more accurate in predicting the effects that can be expected in humans. However, despite all these recent developments there is still not a single therapy available for the treatment of type II diabetes, obesity, frequent urination, and other related diseases. With the exception of the tetrahy- droisoquinoline b 3 -AR agonist 1, a number of papers have described compounds in either the arylethanolamine or aryloxypropanolamine class. Among these analogues, a great deal of structural diversity has appeared in the RHS portion of these analogues distal to the arylethanolamine or aryloxypropanolamine pharmacophore, suggesting a permissive interaction with the receptor in this portion of the molecule. 12) To discover a novel class of potent and selective b 3 -AR agonists, we have synthesized phenylethanolamine derivatives bearing several heterocycles in the RHS of BRL 37344 and CL 316243 (see Chart 2) ; while keeping the LHS 3-chlorophenyl moiety intact as this portion of the molecule, found in a number of other highly selective rat b 3 -AR agonists, is important for b 3 -AR agonistic activity. From the structure-activity relationship (SAR) studies of these derivatives, we have found the novel and selective b 3 -AR, 1-(3-chlorophenyl)-2-[(1H-indol-3-yl)propyl]aminoethanol (31) , as a lead compound with moderate b 3 -AR agonistic activity (rat spontaneous colonic contraction 41) : EC 50 ϭ22.9Ϯ3.1 nM) and weak b 1 -and b 2 -ARs agonistic activity (inhibition of rat uterus spontaneous motility 41) : EC 50 ϭ577.3Ϯ149.4 nM and enhancement of spontaneous beating in guinea-pig isolated right atria 24) : EC 50 ϭϾ10000 nM, respectively). Furthermore, 31 showed more potent human b 3 -AR agonistic activity than SR 58611A and CL 316243. To improve the potency and selectivity of 31, we focused our efforts on the introduction of various substituents into the indole nucleus and its side-chain at the 3-position. It is well-known that the b 3 -AR agonist BRL 37344 essentially requires an (R,R)-configuration at the benzyl position with a hydroxy and an adjacent methyl groups at the amino group to enhance its agonistic activity for rat b 3 -AR. 42) Thus, optical resolution performed on selected compound and further SAR studies of 31 led to the discovery of the optically active [3- 
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[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]acetic acid (96, AJ-9677)
. This compound showed the most potent human and rat b 3 -ARs agonistic activity with low affinity for human b 1 -and b 2 -ARs.
In this paper, we describe the synthesis and SAR studies of a novel series of 1-(3-chlorophenyl)-2-aminoethanol derivatives and investigate their biological activity at human b 1 -, b 2 -, and b 3 -ARs and rat b 3 -AR.
Chemistry
The starting substituted 1H-indoles are commercially available or can be prepared according to the literature. Methyl (1H-indol-6-yloxy)acetate and 7-ethoxy-, 7-propoxy-, 7-isopropoxy-, and 7-(2-ethoxyethoxy)-1H-indoles were prepared by reaction of the commercially available 6-and 7-hydroxy-1H-indoles (2 and 3, respectively) with the corresponding alkylhalides or substituted alkyl halides in the presence of K 2 CO 3 and KI. Treatment of 3 with acrylonitrile in the presence of triton B at refluxing temperature gave the 7-(2-cyanoethoxy)-1H-indole in 89% yield (Chart 3). The requisite intermediate tryptamine derivatives are commercially available or can be prepared from substituted 1H-indoles using usual procedures described in the literature. In general, 3-formyl-1H-indoles obtained by Vilsmeier reaction 43, 44) (POCl 3 /DMF) of the substituted 1H-indoles or the commercially available 3-formyl-1H-indoles were treated with nitromethane or nitroethane in AcOH to produce nitroolefins in good yields. Conjugated nitroolefins were reduced by LiAlH 4 to directly give substituted tryptamines although the yields were moderate to low (Chart 4, method A). Another synthetic route to the substituted tryptamines 45, 46) was as follows (Chart 4, method B): treatment of substituted 1H-indoles with nitroethylene 47) or 2-nitro-1-propene 47) produced from nitro-alcohols provided the corresponding 3-(2-nitroethyl-or 2-nitropropyl)-1H-indoles, which were hydrogenated over Raney-Ni in EtOH (method B-1) or reduced with Fe in the presence of NH 4 Cl in refluxing aqueous EtOH (method B-2) to give the desired tryptamine derivatives in moderate to good yields.
The methyl [3-(2-aminopropyl)-1H-indol-7-yloxy]acetate (8) was prepared from the 3-(2-aminopropyl)-7-benzyloxy-1H-indole (4), which was obtained by method A from the 7-benzyloxy-1H-indole. [48] [49] [50] [51] Protection of 4 by a tert-butoxycarbonyl (Boc) group followed by hydrogenation of the resultant 5 over Pd on carbon gave the 7-hydroxytryptamine 6. Reaction of 6 with methyl chloroacetate in the presence of K 2 CO 3 and KI in refluxing acetone, followed by deprotection of the resultant 7 using aqueous HCl produced the desired tryptamine 8 (Chart 5).
Most of the compounds listed in Tables 1-5 (24-91 except 33, 45-53, 84, 90), were prepared by nucleophilic addition of alkyl amines bearing various heterocycles, tryptophan derivatives, or tryptamine derivatives to the racemic 3-chlorostyrene oxide (9) or its optical isomer 25, [52] [53] [54] [55] [56] [57] (R)-9 in MeOH (Chart 6, method X).
The 1-(3-chlorophenyl)-2-[(1H-indol-3-yl)methyl]aminoethanol (33) was prepared by reductive alkylation. Treatment of the 2-amino-1-(3-chlorophenyl)ethanol 58, 59 ) with 3-formyl-1H-indole, followed by reduction of the intermediate imine with NaBH 4 provided 33 in only 15% yield (Chart 7).
The 1H-indole derivatives 45-49 (Table 2) , having carbamoyl, hydroxymethyl, and carboxylic acid functionalities, respectively were obtained by amidation with ammonia, reduction with LiBH 4 , or alkaline hydrolysis of 43 and/or 44, which were derived from the D-or L-tryptophan methyl esters and 9 using method X, respectively (Chart 8, method Y).
The optically active 1- Table 3 were synthesized by treatment of the optically active 3-chloromandelic acids 60) (R)-10 and (S)-10 with the optically active amethyltryptamines 61) (R)-11 and (S)-11 using benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent) as a coupling reagent, followed by reduction of the amide group of the optically active mandelamides 12-15 with borane in refluxing THF solution (Chart 9).
Protection of the 2-aminoethanol moiety of the 7-benzyloxy-1H-indole derivative 83 with a carbonyl group, and successive separation of the resultant 1,3-oxazolidinone derivative as diastereomeric mixture using silica gel column chromatography afforded the optical isomers 16 and 17 having Rand S-configurations at the a-methyl group, respectively. To avoid removal of the 3-chlorine atom in the benzene ring of 16 and 17, catalytic hydrogenation of 16 and 17 over Pd on carbon in the presence of chlorobenzene or Rh on carbon in EtOH was carried out and the corresponding 7-hydroxy-1H-indole derivatives 18 and 19 were obtained. Treatment of the resulting products 18 and 19 with methyl chloroacetate in the presence of K 2 CO 3 and KI, followed by alkaline hydrolysis of the methyl (1H-indol-7-yloxy)acetates 20 and 21 with aqueous NaOH produced simultaneous ester hydrolysis and deprotection of the 2-aminoethanol moiety giving the desired optically active (1H-indol-7-yloxy)acetic acids 96 and 97. The corresponding methyl esters 94 and 95 of 96 and 97 were obtained in good yields by treatment of 96 and 97 with SOCl 2 in MeOH. In a manner similar to that described for the preparation of 96 and 97 from 18 and 19, methylation of 18 and 19 with MeI and successive alkaline hydrolysis of 22 and 23 afforded the optically active 7-methoxy-1H-indoles 92 and 93 (Chart 10).
The absolute configurations of the optically active 7-benzyloxy-1H-indole derivative 17 [(R,S)-configuration] and 96 [(R,R)-configuration] were confirmed by single-crystal X-ray analysis, and the ORTEP diagram of 96 is shown in Fig. 1 .
Results and Discussion
In order to expedite the identification of potent b 3 -AR agonists, we focused our efforts on optimizing the RHS moiety of BRL 37344 and CL 316243, while keeping the LHS 3-chlorophenyl moiety intact. First, we examined the 1-(3-chlorophenyl)-2-aminoethanol derivatives 24-38 bearing a variety of heterocycles for their inhibition of rat proximal colon spontaneous contraction (rat b 3 -AR agonistic activity) 41) and ability to increase cAMP levels in CHO cells expressing cloned human b 3 -AR at concentration of 10 Ϫ7 M (human b 3 -AR agonistic activity), and compared the results to those of reference compounds SR 58611A and CL 316243. As illustrated in Table 1 , the first generation of b 3 -AR agonists (SR 58611A and CL 316243) exhibited potent rat b 3 -AR agonistic activity. Compounds 24-27 having a pyrrole, thiophene, and pyridine rings, respectively, were essentially inactive or had weak agonistic activity at the rat and/or human b 3 -AR. However, the 1- (28) exhibited modest rat and human b 3 -ARs agonistic activity. Although 28 agonistic activity for rat and human b 3 -ARs was lower than that of SR 58611A, its agonistic activity for human b 3 -AR was higher than that of CL 316243. A significant loss in rat and human b 3 -ARs agonistic activity was observed with the regioisomer of 28, i.e. the 2-benzo[b]thiophene derivative 29. The 3-benzo[b]furan analogue 30 did not show improved rat b 3 -AR agonistic activity, but its human b 3 -AR agonistic activity was more potent than that of 28. To our delight, the 1-(3-chlorophenyl)-2-[(1H-indol-3-yl)propyl]aminoethanol (31) was found to have the most potent human b 3 -AR agonistic activity (Table 1) , with 53% cAMP accumulation at 10 Ϫ7 M. The regioisomer of 31, i.e. the 2-(1H-indole) analogue 32, like the benzo[b]thiophene series, had significantly low rat and human b 3 -ARs agonistic activity. In terms of tether-length modification, a comparison of the data obtained for 33 and 34 with that obtained for 31 indicated that both longer and shorter RHS indole nucleus chains lead to diminished rat and human b 3 -ARs agonistic activity. In addition, replacement of the 1H-indole nucleus of 31 by an indoline, benzoisoxazole, 1H-indazole, or benzothiazole ring (giving 32-38, respectively) considerably reduced the agonistic activity for human b 3 -AR. From the findings above, compound 31 was selected as lead compound and its in vitro ability to inhibit rat uterus spontaneous motility (b 2 -AR agonistic activity) and to induce chronotropic effects on guinea-pig right atria (b 1 -AR agonistic activity) were assayed. Our results show that compound 31 slightly relaxed both rat uterus (b 2 -AR; EC 50 ϭ557.3Ϯ149.4 nM) and guinea-pig atria (b 1 -AR, EC 50 ϭϾ10000 nM) and was therefore characterized as a potent rat b 3 -AR agonist even thought its agonistic activity was weaker than that of SR 58611A or CL 316243. Compound 31 also showed weak agonistic activity at both b 1 -and b 2 -ARs and moderate agonistic activity at human b 3 -AR. Compound 31 was thus classified as a full agonist (ED 50 ϭ62 nM as shown in Table 2 ) at human b 3 -AR with 99% activation relative to (ϩ)-isoproterenol [defined as Intrinsic Activity (IA)Ͼ90%].
Inspection of the structure of the b 3 -AR agonists BRL 37344 and CL 316243 revealed some similarities including the presence of a methyl group at the a-position of the phenethylamine moiety. As expected, introduction of a methyl group (yielding 39, Table 2 ) into the tryptamine sidechain of 31 resulted in an enhancement of b 3 -AR agonistic activity (EC 50 ϭ12 nM, IAϭ114%), when compared with that of 31. However, modification of the alkyl substituent from a methyl to an ethyl group in 39 (yielding 40) significantly reduced the agonistic activity for human b 3 -AR. Eli Lilly scientists have studied a series of amides as anti-obesity/anti-diabetic agents and discovered the potent and selective b 3 -AR agonist LY-377604 having a dimethyl group at the a-position of the phenethylamine moiety (see Chart 1) . 40) In our study, further introduction of a methyl group into 39 (yielding 41) resulted in ca. 6-fold decrease in b 3 -AR agonistic activity (EC 50 ϭ70 nM). Compound 42 having a tetrahydrocarbazole ring like SR 58611A exhibited significantly poor agonistic activity at the b 3 -AR. Furthermore, introduction of other functionalities such as methoxycarbonyl, carbamoyl, hydroxymethyl, and carboxylic acid into 31 (yielding 43-49) remarkably decreased b 3 -AR agonistic activity. As a result of the SAR studies described above, 39 bearing 1H-indole nucleus was selected as a potential human b 3 -AR agonist and the useful RHS was concluded to be 1-(1H-indol-3-yl)-2-propylamine moiety.
From studies on b-ARs agonistic activity of the four optical isomers of BRL 37344, the (R,R)-configuration was proved to be important for enhancing rat b 3 -AR agonistic activity while keeping that for b 1 -and b 2 -ARs low. 42) To study the relationship between the stereoconfiguration of the methyl and hydroxy groups in the selected tryptamine derivative 39 and b-ARs agonistic activity, the four stereoisomers 50-53 were prepared and were assessed by measuring cAMP accumulation in CHO cells expressing cloned human b 1 -, b 2 -, and b 3 -ARs and rat b 3 -AR ( Table 3) . As expected, the optical isomer 50, having R-configuration in both the hy- a) All compounds except for 33 were prepared by method X (See Experimental Section). All compounds were racemic mixture. b) Abbreviation for the solvents used are as follows: Eϭethanol, DEϭdiethyl ether, Tϭtoluene, Hϭhexane. c) All compounds were analyzed for C, H, N, S, and halogen; analytical results were withinϮ0.4% for the theoretical values. d) See Experimental Section. e) Activity relative to (Ϫ)-isoproterenol. f) Oxalic acid. g) NT; not tested. 
Abbreviaion for the solvents used are as follows: Eϭethanol, DEϭdiethyl ether, MϭMethanol. c) See footnote c in Table 1 . d) b 3 -AR agonistic activity was assessed by measurement of cAMP accumulation level in CHO cells expressing human b 3 -AR (150000 receptors/cell). e) The maximal amount of cAMP obtained by (Ϫ)-isoproterenol and the amonunt of cAMP in the absence of agonists were defined as 100 and 0%, respectively, and the relative maximal response of each compound is expressed as intrinsic activity (IA). EC 50 value is a concentration of the test compound to be required to achieve 50% of cAMP accumulation. f) Activity relative to (Ϫ)-isoproterenol. g) Racemic mixture. h) Mixture of four diastereomers. i) Mixture of two diastereomers. j) Fumaric acid. k) Oxalic acid. 
BRL 37344
17 (89) 380 (20) 1100 ( Table 2 . g) NT: not tested. h) Enantiomeric excess; Ͼ99.5%, diastereomeric excess; Ͼ99.5%. i) Enantiomeric excess; Ͼ99.5%, diastereomeric excess; Ͼ99.5%. j) Could not be calculated because of Low IA. k) Oxalic acid. l) Enantiomeric excess; Ͼ99.5%, diastereomeric excess; 99.5%. m) Enantiomeric excess; Ͼ99.5%, diastereomeric excess; 98%. Next, to find selective and more potent human b 3 -AR agonists, we introduced various substituents into the 1H-indole nucleus. Introduction of an electron-donating group such as methyl and methoxy groups at 1-, 2-, 4-, 5-, 6-, or 7-position of the indole nucleus of 31 and 39 gave a mixture of two diastereomers and four diastereomers 54-69 ( Table 4) . The 1-, 2-, 4-, 5-, and 7-methyltryptamine derivatives 54-58, 61, 62 displayed lower human b 3 -AR agonistic activity than the parent compound 31 or 39. On the other hand, the 6-methyltryptamines 59 and 60 displayed ca. 2-fold more potent, or comparable, b 3 -AR agonistic activity than their parents 31 and 39. In the methoxytryptamines 63-68, on the other hand, the 7-methoxytryptamine 68 exhibited a dramatic improvement in b 3 -AR agonistic activity with a much more potent human b 3 -AR agonistic activity (EC 50 ϭ1.7 nM, IAϭ 113%) than that of 39 and the des-methyl counterpart 67. Other methoxytryptamines (63-67) had low or moderate agonistic activity at the human b 3 -AR. Introduction of two methoxy groups at the 6-and 7-positions (yielding 69) resulted in a well tolerated b 3 -AR agonistic activity. Compound 70 with a more bulky 6-benzyloxy group was a weak human b 3 -AR agonist compared with 66. On the contrary, human b 3 -AR agonistic activity of the 6-methoxycarbonylmethoxytryptamine 71 was comparable to that of 66. Encouraged by these results, we prepared and tested tryptamine derivatives with an electron-withdrawing group. In the tryptamine derivatives 72-79 with a halogeno group at the 4-, 5-, and 6-positions, the 6-substituted tryptamines exhibited moderate or potent human b 3 -AR agonistic activity. In particular, the 6-fluorotryptamine 79 showed potent b 3 -AR agonistic activity (EC 50 ϭ5.7 nM, IAϭ90%). Compounds 80 and 81 with CF 3 and ethoxycarbonyl groups had an agonistic activity nearly equipotent to that of the corresponding 6-chlorotryptamine 75. On the basis of human b 3 -AR agonistic activity, compound 68 bearing a 7-methoxy group in the indole nucleus showed the most potent activity and was selected for further modifications of the O-substituent at the 7-position. From the above SAR studies on the configuration of the hydroxy center, the R-configuration was proved to be important for potent human b 3 -AR agonistic activity. Thus, 7-O-substituted indole analogues with a (R)-hydroxy group were prepared and tested for their agonistic activity at the human b 3 -AR. As shown in Table 5 , the 7-methoxyindole derivative 82 showed an agonistic activity ca. 2.5-fold more potent than that of the mixture of the four diastereomers of 68. Replacement of the methoxy group of 82 by a bulky benzyloxy group (yielding 83) caused a profound decrease in agonistic activity. Removal of the benzyl group of 83 gave the 7-hydroxytryptamine 84, which exhibited a slightly decreased agonistic activity at the human b 3 -AR as compared to the 7-methoxytryptamine 82. When the methoxy group of 82 was replaced with an alkoxy group such as ethoxy (85) , propoxy (86), or isopropoxy (87) groups, no favorable influence on the agonistic activity was detected. The agonistic activity of the 7-ethoxytryptamine 85 was practically comparable or somewhat inferior to that of the 7-methoxytryptamine 82. However, other compounds 86 and 87 showed ca. 20-fold and 4-fold, respectively, lower agonistic activity than that of 82. Next, introduction of an electron-withdrawing group such as methoxycarbonyl, cyano, or free carboxylic acid into the 7-alkoxy group of 82 and 85 was carried out. Compounds 88 and 89 with methoxycarbonyl and cyano groups were essentially equipotent to the corresponding 7-methoxy and 7-ethoxytryptamines 82 and 85. Interestingly, the acetic acid derivative 90 showed much more potent agonistic activity than the 7-methoxy and the 7-methoxycarbonylmethoxytryptamines 82 and 88 and conferred the highest human b 3 -AR agonistic activity (EC 50 ϭ0.11 nM, IAϭ124%). It is unclear whether the superiority of the acetic acid 90 relative to the methoxy analogue 82, the methyl ester 88, and the cyano analogue 89 is a result of the presence of an acidic proton or subtle conformational difference that permits a more favorable interaction with the human b 3 -AR (relative to b 1 -and b 2 -ARs) in the acetic acid analogue. On the other hand, introduction of an electron-donating group such as ethoxy group (yielding 91) into the 7-ethoxy group of 85 caused a decrease in agonistic activity. As a result of the SAR studies described above, the optimum 7-substituent for the indole nucleus was concluded to a carboxylmethoxy group.
Finally, the 7-methoxy, 7-methoxycarbonylmethoxy, and 7-carboxylmethoxyindole derivatives (82, 88, and 90, respectively) with potent agonistic activity at the human b 3 -AR were selected for diastereomers separation and agonistic activity examination at the human b 1 -, b 2 -, and b 3 -ARs and rat b 3 -AR (Table 6 ). The optical isomers 92, 94, and 96 with an (R)-a-methyl group showed much more potent agonistic activity than the corresponding diastereomers 93, 95, and 97, respectively. However, 92 and 94 exhibited poor selectivity for human b 3 -AR as they potently stimulated both human the b 1 -and b 2 -ARs. On the other hand, 96 had an outstanding profile with respect to its agonistic activity for both human and rat b 3 -ARs (EC 50 ϭ0.062 and 0.016 nM, IAϭ116 and 110%, respectively) with a selectivity for human b 3 -AR over 100-fold that for the b 1 -AR (EC 50 ϭ6.4 nM, IAϭ26%) and 200-fold that for the b 2 -AR (EC 50 ϭ13 nM, IAϭ26%). A comparison between human b 3 -AR agonistic activity of the carboxylic acid derivative 96 and that of the corresponding ester 94 indicated that acidity of the carboxylic acid substituent in the RHS indole nucleus led to a remarkably increased (ca. 10-fold) activity at the human b 3 -AR and enhanced selectivity at both the b 1 -and b 2 -ARs. This result is consistent with published data from earlier SARs [62] [63] [64] [65] studies indicating that carboxylic acids are usually more selective than the corresponding esters. On the other hand, 50, which lacks substituent on the RHS of the indole nucleus, displayed the most potent b 1 -AR agonistic activity with a modest human b 3 -AR agonistic activity. In addition, compound 92 having a 7-methoxy group in the indole nucleus showed the most potent b 2 -AR agonistic activity as compared to 96. Thus, the role of the carboxylic acid substituent in the RHS indole nucleus of 96 can be revealed by comparing its b-AR profile to that of the analogues 50, 92, and 94. These findings indicate that the presence of a 7-carboxylmethoxy group and an R-configuration for the a-methyl group are necessary for potent b 3 -AR agonistic activity and selectivity against human b 1 -and b 2 -ARs.
Since compound 96 showed the best in vitro profile with respect to humans b 3 -AR agonistic activity and selectivity, we decided to investigate its ability to elicit in vivo b 3 -AR mediated response (anti-obesity and anti-diabetic effects). Compound 96 (0.1 mg/kg) was orally administrated into genetically diabetic obese KK-A y /Ta mice for 14 d. Control KK-A y /Ta diabetic obese mice exhibited marked hyperglycemia, hyperinsulinemia, hypertriglyceridemia, and high free fatty acid (FFA) levels compared with normal C57BL/6J mice (Fig. 2) . In the mice treated with 96, plasma glucose concentration and plasma insulin concentration decreased. Furthermore, 96 significantly reduced FFA and triglyceride (TG) concentrations in plasma. These results suggest that 96 stimulates lipid metabolism and improves insulin resistance in diabetic obese mouse model. As shown in Fig. 3 , although treatment with 96 (0.1 mg/kg, p.o.) did not alter total food intake (control mice; 87.0Ϯ4.0 g vs. 96-treated mice; 87.0Ϯ 2.9 g), no increase in body weight was observed in diabetic obese mice after 14 d (control; 38.1Ϯ0.6 g to 40.2Ϯ0.7 g vs. 37.8Ϯ0.8 g to 37.8Ϯ1.1 g). It is therefore believed that compound 96 would be useful for the treatment of type II diabetes and obesity.
Conclusion
In this study, replacement of RHS moiety of BRL 37344 and CL 316243 with a heterocycle and further introduction of a variety of substituents on the RHS indole nucleus of the lead compound 31 resulted in the identification of a number of potent and full agonists at the human b 3 -AR. In particular, introduction of a polar carboxylic acid functionality at the Vol Table 3 . b-e) See footnotes c-f in Table 3 . f) Could not be calculated because of low IA. g) Oxalic acid. h) Fumaric acid. i) NT: not tested.
position of the indole nucleus diminished both b 1 -and b 2 -ARs agonistic activity and increased the that for human b 3 -AR. Optical resolution of 90 having a carboxylic acid functionality gave 96 (AJ-9677) with an (R,R)-configuration at the benzyl position, and a hydroxy group and adjacent methyl group at the amino group. Compound 96 exhibited potent human b 3 -AR full agonistic activity and good selectivity for human b 3 -AR over human b 1 -and b 2 -ARs. More importantly, we were pleased to discover that the most promising compound 96 we have found exhibits not only strong human b 3 -AR agonistic activity with high b 1 /b 3 and b 2 /b 3 selectivity ratios but also strong rat b 3 -AR potency (EC 50 ϭ0.016 nM, IAϭ110%).
Finally, repeated oral administration of 96 inhibited body weight gain and significantly decreased glucose, insulin, free fatty acid, and triglyceride concentrations in plasma in KK-A y /Ta mice. On the basis of this pharmacological profile, 96 entered clinical development as a drug for the treatment of type II diabetes and obesity.
Experimental
All melting points were determined on a Yanagimoto micromelting point apparatus without correction. IR spectra were recorded on a Shimadzu FTIR-8200 spectrometer with KBr disks. Atmospheric pressure chemical ionization mass spectra were obtained on a Hitachi M-1000 spectrometer. 2-(2-aminoethyl)-1H-indole, 82) 3-(3-aminopropyl)-1H-indole, 83) 3-(3-aminopropyl)-7-methoxy-1H-indole.
84)
Methyl (1H-Indol-6-yloxy)acetate A mixture of the commercially available 6-hydroxy-1H-indole (2.9 g, 22 mmol), methyl chloroacetate (2.7 g, 25 mmol), K 2 CO 3 (5.5 g, 40 mmol), KI (0.2 g), and acetone (100 ml) was heated to reflux for 8 h and cooled to room temperature. The insoluble materials were removed by filtration, and the filtrate was concentrated to dryness. The residue was chromatographed on silica gel with CHCl 3 to give 2.8 g (63%) of the title compound as an oil. 1 
. In a manner similar to that described above, 7-ethoxy-, 7-propoxy-, 7-isopropoxy-, and 7-(2-ethoxyethoxy)-1H-indoles were prepared from 7-hydroxy-1H-indole and the corresponding halides (iodoethane, 1-bromopropane, 2-iodopropane, 2-bromoethyl ethyl ether) in N,N-dimethylformamide (DMF) instead of acetone at 90°C.
7-(2-Cyanoethoxy)-1H-indole
A mixture of 7-hydroxy-1H-indole (5.0 g, 38 mmol), triton B (0.5 ml), and acrylonitrile (9 ml, 0.14 mol) was heated to reflux for 20 h and cooled to room temperature. The reaction mixture was concentrated to dryness, and the residue was purified by silica gel column chromatography with AcOEt/hexaneϭ2/1 to give 6.2 g (89%) of the title compound as an yellow oil. Method A. General Procedure (1) Phosphorus oxychloride (5 ml) was added dropwise to DMF (16 ml) under ice-cooling. The mixture was stirred at the same temperature for 10 min. A solution of substituted 1H-indole (44 mmol) in DMF (16 ml) was added dropwise to the mixture at ca. 5°C. After the temperature was raised to room temperature, the mixture was stirred for 2 h. Then, 30% aqueous NaOH (30 ml) was added under ice-cooling, and the mixture was heated at 80°C for 5 min and cooled to room temperature. The resulting precipitate was collected by filtration, washed with water, and dried to give of substituted 3-formyl-1H-indole.
(2) A mixture of ammonium acetate (3.6 g, 47 mmol), Ac 2 O (1 ml), and AcOH (3.2 ml) was heated at 50°C for 20 min. After addition of substituted 3-formyl-1H-indole (26 mmol), nitromethane or nitroethane (16 ml), and AcOH (19.2 ml), the mixture was raised to 100°C and AcONa (2.25 g, 27 mmol) was added. The whole was heated to reflux for 2 h while Ac 2 O (3.2 ml) was gradually added dropwise. After being cooled to room temperature, water was added to the resulting mixture. The precipitate was collected by filtration, washed with water, and dried to afford of 1-(substituted 1H-indol-3-yl)-2-nitroethylene or -2-nitropropene.
(3) A solution of 1-(substituted 1H-indol-3-yl)-2-nitropropene or -2-nitroethylene (14 mmol) in anhydrous THF (60 ml) was added dropwise to a suspension of LiAlH 4 (3.2 g, 84 mM) in anhydrous Et 2 O (60 ml) under icecooling. The mixture was heated to reflux for 5.5 h and cooled to ca. 5°C. A saturated aqueous sodium potassium tartarate was carefully added to the mixture at the same temperature, and the insoluble materials were removed by filtration. The filtrate was dried over anhydrous MgSO 4 . The solvent was evaporated to give substituted 3-(2-aminoethyl or propyl)-1H-indole, which was used in the next step without further purification.
Method B-1. Typical Procedure; Methyl [3-(2-Aminopropyl)-1H-indol-6-yloxy]acetate (1) A mixture of methyl (1H-indol-6-yloxy)acetate (2.8 g, 14 mmol), 2-nitro-1-propene (3.6 g, 41 mmol), and benzene (68 ml) was heated to reflux for 15 h and cooled to room temperature. The solvent was evaporated, and the residue was chromatographed on silica gel with CHCl 3 to give 2.15 g (54%) of methyl [3-(2-nitropropyl)-1H-indol-6- 2 mmol) in EtOH (50 ml) was hydrogenated over Raney-nickel (ca. 100 mg) at 50°C under atmospheric pressure. After the theoretical amount of hydrogen was consumed, the catalyst was filtered off. The filtrate was concentrated to dryness to give ca. 1.9 g (quantitative yield) of the title compound as an oil, which was used in the next step without further purification. (2) A solution of crude 7-(2-cyanoethoxy)-3-(2-nitropropyl)-1H-indole (6.0 g) in EtOH (50 ml) was added to a mixture of Fe (12 g, 0.21 mol), NH 4 Cl (3.0 g, 56 mmol), EtOH (100 ml), and water (100 ml) at room temperature. The mixture was heated to reflux for 2.5 h and cooled to room temperature. The insoluble materials were filtered off, and the volatiles were evaporated. After addition of aqueous K 2 CO 3 to the resulting aqueous solution, the mixture was extracted with CHCl 3 . The extract was washed with brine and concentrated to dryness to give 2.3 g (30% yield for 2 steps) of the title compound as a brown oil, which was used in the next step without further purification. MS m/z: 244 (MH ϩ ).
Methyl [3-(2-Aminopropyl)-1H-indol-7-yloxy]acetate (8) (1)
A solution of 3-(2-aminopropyl)-7-benzyloxy-1H-indole (4, 3.7 g, 13 mmol), ditert-butyl dicarbonate (2.9 g, 13 mmol), and Et 3 N (1.8 ml, 13 mmol) in CHCl 3 (50 ml) was stirred at room temperature for 16 h. The reaction mixture was washed successively with water, 10% aqueous citric acid, water, and brine and dried over anhydrous MgSO 4 . The solvent was evaporated and the residue was chromatographed on silica gel with CHCl 3 to 4.0 g (80%) of 7-benzyloxy-3-[2-(tert-butoxycarbonyl)aminopropyl]-1H-indole (5) as a white solid, which was used in the next step without further purification.
(2) A solution of 5 (8.0 g, 21 mmol) in EtOH (80 ml) was hydrogenated at atmospheric pressure over 10% Pd on carbon (0.8 g) at ca. 50°C. After the theoretical amount of hydrogen was absorbed, the catalyst was filtered off. The filtrate was concentrated to dryness to give ca. 6 g of 3-[2-(tert-butoxycarbonyl)aminopropyl]-7-hydroxy-1H-indole (6) as an oil.
(3) A mixture of crude 6 (ca. 6 g, ca. 21 mmol), methyl chloroacetate (2.3 g, 21 mmol), K 2 CO 3 (2.9 g, 21 mmol), KI (0.2 g), MeOH (40 ml), and acetone (80 ml) was heated to reflux for 4 h and cooled to room temperature. After the insoluble materials were filtered off, the filtrate was concentrated to dryness. The residue was chromatographed on silica gel with AcOEt/ hexaneϭ2/3 to give 4.5 g (59% yield from 5) of methyl [3-[2-(tert-butoxycarbonyl)aminopropyl]-1H-indol-7-yloxy]acetate (7) 1-(3-Chlorophenyl)-2-[2-(1H-indol-3-yl) 1-(3-Chlorophenyl)-2-[2-(6-trifluoromethyl-1H-indol-3-yl) 
. (1R)-(3-Chlorophenyl)-2-[2-(7-methoxy-1H-indol-3-yl) 
. (1R)-(3-Chlorophenyl)-2-[2-(7-ethoxy-1H-indol-3-yl) 1-(3-Chlorophenyl)-2-[3-hydroxy-(2R)-(1H-indol-3-yl) propyl]aminoethanol Oxalate (47) To a mixture of the free base of 43 (1.12 g, 3.0 mmol), anhydrous LiCl (0.25 g, 5.9 mmol), NaBH 4 (0.22 g, 5.8 mmol), and anhydrous THF (10 ml) was added dropwise anhydrous EtOH (20 ml) under ice-cooling. The mixture was stirred at ca. 20°C for 16 h and concentrated to dryness. The resultant residue was diluted with water and extracted with CHCl 3 . The extract was washed with brine, and the solvent was evaporated. The residue was chromatographed on silica gel with CHCl 3 /MeOHϭ10/1 to give 0.42 g (41%) of the free base of 47 as an oil. The oil was converted to the oxalate in usual manner. (2R)-[2-(3-Chlorophenyl)-2-hydroxyethyl]amino-3-(1H-indol-3-yl) propionic Acid (49) A mixture of the free of 43 (1.0 g, 2.7 mmol), 1 N aqueous NaOH (5 ml, 5.0 mmol), and MeOH (5 ml) was stirred at room temperature for 3 h. After being cooled to ca. 5°C, 1 N aqueous HCl (5 ml) was added to the reaction mixture. The resulting precipitate was collected by filtration, washed successively with water and 20% aqueous MeOH, and dried to give 0.62 g (64%) of 49 as a white crystal. 1R)-(3-Chlorophenyl)-2-[(2S)-(1H-indol-3-yl) propyl]-aminoethanol Oxalate (51) (1) Triethylamine (1.1 ml, 7.9 mmol) was added to a mixture of (R)-(Ϫ)-3-chloromandelic acid [(R)-10, 840 mg, 4.5 mmol], (S)-3-(2-aminopropyl)-1H-indole [(S)-11, 780 mg, 4.5 mmol], benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (1.99 g, 4.5 mmol), and DMF (10 ml) at ca. 20°C. The mixture was stirred at the same temperature for 2 h. After addition of AcOEt, the solution was washed successively with water, 10% aqueous HCl, water, 1 N aqueous NaOH, water, and brine. The organic solution was dried over anhydrous Na 2 SO 4 and concentrated to give ca. (2) 1 M Borane-THF complex (20 ml, 20 mmol) was added dropwise to the solution of 13 (ca. 1.5 g) in anhydrous THF (30 ml) at ca. 20°C. The mixture was heated to reflux for 4 h and cooled to ca. 5°C. After careful addition of MeOH (10 ml), the mixture was heated to reflux for 1.5 h and cooled to room temperature. The solvent was evaporated and the residue was dissolved in AcOEt. The solution was washed successively with water and brine and dried over anhydrous Na 2 SO 4 . The solvent was evaporated and the residue was chromatographed on silica gel with CHCl 3 /MeOHϭ15/1 to 10/1 to give 730 mg [49% from (R)-10] of the free base of 51 as a reddish oil. ). The oil was converted to the oxalate in usual manner. In a manner similar to that described above, 50 was obtained from 12 in 58% yield. . In a manner similar to that described above, the corresponding enantiomers 53 and 52 of 51 and 50, respectively, were prepared from (S)-10 and (R)-11 or (S)-11.
By chiral HPLC analysis under the conditions described below, the optical purity of 50-53 was determined. Retention time of HPLC: 50; 14.7 min, 51; 27.7 min, 52; 16.4 min, 53; 18.3 min. Separation conditions for HPLC: Column; Ultron ES-OVM (4.6 mmfϫ150 mm; Shinwa Chemical Industries, Ltd., Japan), Eluent; 20 mM aqueous KH 2 PO 4 (pH 3.6)/(MeOH/ MeCNϭ3/1)ϭ92/8, Flow rate; 1.0 ml/min, Temperature; 25°C, Detection; 220 nm.
1-(3-Chlorophenyl)-2-[(1H-indol-3-yl)methyl]aminoethanol (33)
A mixture of 3-formy-1H-indole (730 mg, 5.0 mmol), 2-amino-1-(3-chlorophenyl)ethanol (940 mg, 5.5 mmol), NaHCO 3 (630 mg, 7.5 mmol), and MeOH (10 ml) was heated to reflux for 3 h and cooled to ca. 5°C. After addition of NaBH 4 (280 mg, 7.4 mmol), the reaction mixture was stirred at room temperature for 2 h and concentrated to dryness. The residue was dissolved in a mixture of water and CHCl 3 , and the organic layer was separated and dried over anhydrous MgSO 4 . The solvent was evaporated, and the residue was chromatographed on silica gel with CHCl 3 /MeOHϭ9/1 to give 230 mg (15% from 3-formyl-1H-indole) of 33 as a solid. (3-chlorophenyl)-1,3-oxazolidin-2-ones (16, 17) (1) A solution of 3-(3-aminopropyl)-7-benzyloxy-1H-indole (4, 9.0 g, 32 mmol) and (R)-9 (3.1 g, 20 mmol) in MeOH (100 ml) was stirred at room temperature for 28 h and concentrated to dryness. The residue was chromatographed on silica gel with CHCl 3 /MeOHϭ20/1 to CHCl 3 /MeOH/saturated aqueous NH 3 ϭ 10/1/0.1 to give 4.1 g [47% from (R)-9] of 83 as a pale brown solid and to recover 3.1 g (34%) of 4 as a pale yellow solid in that order.
3-[(2R)-and 3-[(2S)-(7-Benzyloxy-1H-indol-3-yl)propyl]-(5R)-
(2) A mixture of 83 (3.9 g, 9.0 mmol), N,NЈ-carbonyldiimidazole (CDI, 3.1 g, 19 mmol), Et 3 N (7.9 ml, 57 mmol), and THF (40 ml) was stirred at room temperature for 16 h and concentrated to dryness. The residue was dissolved in AcOEt, and the solution was washed successively with water, 10% aqueous citric acid, water, and brine and dried over anhydrous Na 2 SO 4 . The solvent was evaporated and the residue containing a mixture of 16 and 17 was chromatographed on silica gel with AcOEt/hexaneϭ1/3 to 1/1 to give 2.0 g (48%) of 16 as a pale brown oil and 1.5 g (36%) of 17 as a pale brown oil in that order. 81 mmol), NaOH (0.9 g, 22.5 mmol), water (4.5 ml), and EtOH (9 ml) was heated to reflux for 18 h and cooled to room temperature. After evaporation of the volatiles, the residue was dissolved in 2 N aqueous HCl (15 ml). The solution was purified by CHP 20P (75-150 m, Mitsubishi Chemical Co., Ltd., Japan) with water to 70% aqueous MeCN, and the fractions containing 96 were collected. The solvent was evaporated, and the residue was dissolved in a mixture of EtOH and Et 2 O. After reevaporation of the volatiles, the residual solid was triturated with aqueous EtOH to give 0. 
. In a manner similar to that described above, 95 was prepared from 97. (1R)-(3-Chlorophenyl)-2-[(2R)-(7-methoxy-1H-indol-3-yl)propyl]-aminoethanol (92) and (1R)-(3-Chlorophenyl)-2-[(2S)-(7-methoxy-1H-indol-3-yl) 3 , and 11.5 mmol glucose containing 12 mmol phenoxybenzamine) in a 20 ml organ bath maintained at 37°C and aerated with 95% O 2 , 5% CO 2 . The number of spontaneously beating was recorded isometrically under a constant load of 1 g. After 30 min, tested compounds were added cumulatively.
Cloning of Various b b-AR cDNAs and Establishment of the Cell Lines Expressing Them Human b 3 -AR cDNA was cloned from total RNA extracted from human neuroblastoma cell SK-N-MC (ATCC HTB 10). The sequence of the cDNA was identical with that reported by Lelias et al. 85) The cDNA was inserted to pKCN1, a plasmid vector containing SV40 promoter and G-418 resistant gene. This plasmid was named as pKREX10. The Chinese hamster ovary cell line CHO-K1 (ATCC CCL61) was transformed with the pKREX10 by calcium phosphate method and transformants were selected with antibiotics G-418. Sixty-nine G-418 resistant clones were harvested and disrupted by low osmotic pressure. This suspension was incubated with (Ϫ)-3-[ 125 I]iodocyanopindolol at 4°C for 2 h and the reaction mixture was filtered and washed with glass filter and radioactivity on the filter was counted. One clone named CHO/pKREX10-36, which showed highest radioactivity, was used for human b 3 -AR-expressing cell line. Rat b 3 -AR, human b 1 -AR, and human b 2 -AR cDNAs were cloned from fat cell cDNA library RL1011b (Clontech), total RNA from human neuroblastoma cell SK-N-MC, and mRNA derived from human whole brain (Clontech 6516-1), respectively. Each cDNA was inserted to expression vector pKCN1 and introduced into CHO-K1 cell as in the case of human b 3 -AR. Resulting cell lines CHO/pKREX6-47, CHO/pKREX23-46, and CHO/pKREX21-8 were used as rat b 3 -AR-, human b 1 -AR-, and human b 2 -AR-expressing cells, respectively.
Measurement of Intracellular cAMP Accumulating Activity The cells were peeled off and suspended with Hanks' balanced salts containing 1 mmol L-ascorbic acid and 1 mM 3-isobutyl-1-methylxanthine. This suspension and each test compound were incubated at 37°C for 30 min, followed by boiling for 5 min to terminate the reaction. After centrifugation, the amount of cAMP in the supernatant was measured by enzyme immunoassay. The maximal amount of cAMP obtained by (Ϫ)-isoproterenol or the amount of cAMP when not adding any agonists were defined as 100% and 0%, respectively, and the relative maximal response of each compound is expressed as intrinsic activity (IA). EC 50 value which is a concentration of the test compound to be required to achieve 50% of cAMP accumulation was calculated by least squares regression analysis of concentration-response curve of each compound.
Animals and Drug Treatment Male 9-week-old KK-A y /Ta mice and 11-week-old C57BL/6J mice were purchased from Clea Japan, Inc. (Tokyo, Japan) and allowed to adjust to the facilities and handling for 1 week before all experimental protocols. Under standardized conditions, mice were given solid chow (CE-2; Oriental Yeast, Tokyo, Japan) and water ad libitum. KK-A y /Ta mice were divided into the control and treatment groups so that the mean body weight of the two groups was comparable one day before the starting day (day 1). The treatment group was given 96 by gavage at 0.1 mg/kg/d in the morning for 14 d. The control group was given only 0.5% tragacanth solution. Twenty-four hours after the last administration of 96, blood samples were collected from the cut ends of the tails and centrifuged to separate plasma. Blood samples from 12-week-old C57BL/6J mice were also collected by the same method. Concentrations of glucose, insulin, free fatty acid (FFA), and triglyceride (TG) in plasma were measured by commercially available kits.
Single-Crystal X-Ray Analysis. ; Tϭ298 K; crystal size, 0.2ϫ0.08ϫ0.02 mm. All measurements were made on a Rigaku AFC5R diffractometer with graphite monochromated CuKa(lϭ1.54178 Å). The cell constants and orientation matrix for data collections in the range 6.57°ϾqϾ12.52°. The data were collected using the w-2q scan technique to a maximum 2q value of 135.18. Scans of (1.26ϩ0.30 tanq)°were made at a speed of 8.0°min
Ϫ1
. Stationary background counts were recorded in each side of the reflections. A total of 2772 reflections were collected. The intensities of three representative reflections were measured after every 150 reflections. No decay correction was applied. The data were corrected for Lorenz and polarization effects. A correction for secondary extinction was applied. The structure was solved by direct methods (SIR92) and expanded using Fourier technique (DIRDIF94). The nonhydrogen atoms were refined with anisotropic temperature factors. All hydrogen atoms were included at idealized positions but not refined. The final cycle of full matrix least-squares refinement (SHELXL-97) was based on 1879 observed reflections and 255 variable parameters. All calculations were performed using the teXsan (Molecular Structure Co.). A refinement of the Flack's c parameter was carried out to determine the absolute configuration. The value of refined c [0.00 (6) ] indicated that to be the correct absolute stereochemistry. The final R value was 0.065. The standard deviation of an observation of unit weight (goodness of fit) was 1.57. The maximum and minimum peaks on the final difference Fourier map corresponded to 0.32 and Ϫ0.42 e Ϫ /A 3 , respectively. Further details of the X-ray structure are available from the Cambridge Crystallographic Data Centre (deposition number CCDC 203815).
